Drug

SPC-15

Targeted prophylactic treatment—Stress-induced affective disorders

Columbia University CELA

Drug:

Novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment.

  • Pre-IND submitted for first-in-human trials.

Unmet need:

  • No new drug approvals for PTSD in nearly 25 years.
  • Affects estimated 3.9% of world’s population.
  • Cumulative prevalence in young people doubled from 2017 to 2022 to 7.5%.

Medical needs:

  • Selective intranasal drug compound (non-psychedelic).
  • Patented nose-to-brain delivery bypasses blood-brain barrier.
  • Direct, heightened drug concentration in the brain.
  • Optimized patient safety and therapeutic delivery.
Previous Drug
Next Drug

Competitive advantages:

  • Patented, cutting-edge intranasal nose-to-brain drug dispersion.
  • Nose-to-brain method increases drug’s concentration in the brain.
  • Faster onset of therapeutic benefit and optimized safety.
Previous Drug
Next Drug

Get more information on Silo Pharma. Sign up for email alerts online.

SIGN UP